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ABSTRACT
A semi-national laboratory-based surveillance programme for fungaemia was initiated in 2003 that now
covers c. 3.5 million inhabitants (64%) of the Danish population. In total, 1089 episodes of fungaemia
were recorded during 2004–2006, corresponding to an annual incidence of 10.4 ⁄ 100 000 inhabitants. The
annual number of episodes increased by 17% during the study period. Candida spp. accounted for 98%
of the fungal pathogens. Although Candida albicans remained predominant, the proportion of C. albicans
decreased from 66.1% in 2004 to 53.8% in 2006 (p <0.01), and varied considerably among participating
departments, e.g., from 51.1% at a university hospital in Copenhagen to 67.6% in North Jutland County.
Candida glabrata ranked second, and increased in proportion from 16.7% to 22.7% (p 0.04). Candida krusei
was isolated rarely (4.1%), but the proportion doubled during the study period from 3.2% to 6.4%
(p 0.06). MIC distributions of amphotericin B and caspofungin were in close agreement with the
patterns predicted by species identiﬁcation; however, decreased susceptibility to voriconazole, deﬁned
as an MIC of >1 mg ⁄L, was detected in one (2.5%) C. glabrata isolate in 2004 and in 12 (14.0%) isolates in
2006 (p 0.03). Overall, the proportion of isolates with decreased susceptibility to ﬂuconazole exceeded
30% in 2006. The incidence of fungaemia in Denmark was three-fold higher than that reported from
other Nordic countries and is increasing. Decreased susceptibility to ﬂuconazole is frequent, and a new
trend towards C. glabrata isolates with elevated voriconazole MICs was observed.
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INTRODUCTION
A semi-national surveillance programme for fun-
gaemia was initiated in Denmark in 2003, with a
notably high incidence of 11 episodes ⁄ 100 000
inhabitants being recorded during the ﬁrst year
[1]. With this background, the surveillance
scheme was continued and extended to cover
64% of the Danish population. In three other
Nordic countries, the incidence of candidaemia
has been in the range of 2.2–3.5 ⁄ 100 000, with
67–70% of cases being caused by Candida albicans
[2–4]. In European surveys, incidences of
2.5–5.0 ⁄ 100 000 have been reported [5–8], with
56% (43–67%) of the cases in a recent European
study covering France, Germany, Austria, Spain,
Sweden and the UK being caused by C. albicans
[9], while incidences of 6.0–8.7 ⁄ 100 000 have been
reported in most population-based studies in the
USA [10,11]. One major exception is a study that
reported an incidence of 7.1 ⁄ 100 000 in Connect-
icut and 24 ⁄ 100 000 in Baltimore, despite the fact
that the incidences calculated in terms of number
of discharges were comparable [12].
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C. albicans remains the predominant species on
both sides of the Atlantic Ocean, with frequencies
varying from c. 50% in North America and Spain
to c. 70% in recent studies from Norway and
Finland [2,4,13]. The proportion of Candida
glabrata isolates has remained constant overall,
at 9.5–12.0% according to the ARTEMIS DISK
surveillance programme for 1997–2003, which
now includes >130 000 isolates from 39 countries
[14]. Geographical differences exist, with a higher
proportion of C. glabrata isolates in the USA
(c. 20%) than in most other countries (4–14%)
[2,3,9,15,16]. In this context, the ﬁrst years of
surveillance in Denmark revealed an unexpect-
edly high proportion of C. glabrata (20%) [1]. The
present article describes the results from the ﬁrst
3 years of the continued programme (2004–2006),
which now covers two-thirds of the Danish
population, thereby providing the most compre-
hensive study of fungaemia in Denmark to date.
MATERIALS AND METHODS
Surveillance and population
During the 3-year period from January 2004 to December 2006,
fungal blood isolates were collected at the eight major Danish
departments of clinical microbiology at Rigshospitalet and
Hvidovre Hospital (serving Copenhagen City hospitals and
the island of Bornholm since 1 January 2005), Herlev Hospital
(serving hospitals in the county of Copenhagen), Statens
Serum Institut (serving hospitals in Bornholm during the
period 1 January 2004 to 31 December 2004 and the county of
Roskilde), Hillerød Hospital (serving hospitals in the county of
Frederiksborg), Odense University Hospital (serving hospitals
in the county of Funen), Skejby Hospital (serving hospitals in
the county of Aarhus), and Aalborg Hospital (serving hospitals
in the county of North Jutland). Together, the eight depart-
ments served 13 university and 28 district hospitals in the
municipality of Copenhagen and the respective counties, with
a total of 11 033 hospital beds (67.8% of the total non-
psychiatric hospital beds in Denmark). In total, these hospitals
served a total population of 3 490 465–3 509 803 (2004–2006) or
64.5% of the Danish population. In addition, the university
hospitals were secondary- or tertiary-care centres for the entire
country. In particular, all solid-organ transplantations and
autologous bone marrow transplantations in Denmark were
performed at the participating hospitals, and all allogenic bone
marrow transplantations and liver transplantations were
performed at Rigshospitalet. However, it was not feasible to
analyse the referred cases separately. The characteristics of the
eight participating departments of clinical microbiology are
summarised in Table 1. Information concerning the number of
non-psychiatric admissions was retrieved from http://
www.sundhedsdata.sst.dk.
During the study period, four departments used the
BacT ⁄ALERT (bioMe´rieux, Marcy l’Etoile, France) blood cul-
ture system and four used the BACTEC (Becton Dickinson,
Franklin Lakes, NJ, USA) blood culture system. Information
concerning the total number of bloodstream isolates was
retrieved from each department’s laboratory information
system. Successive blood cultures that yielded fungi from the
same patient were considered to be distinct episodes if they
occurred ‡21 days apart or were caused by different species.
Most (90.5%) of the isolates were sent to the reference
laboratory (Unit of Mycology and Parasitology, Statens Serum
Institut, Copenhagen, Denmark) for veriﬁcation of species
identiﬁcation and susceptibility testing, but 108 (9.5%) isolates
were not referred and no susceptibility data for these isolates
were available for analysis. In addition, voriconazole suscep-
tibility testing was not performed for 74 (6.5%) isolates
collected in January–March 2004, as this was not commenced
until 1 April 2004.
Species identiﬁcation
Species identiﬁcation at the reference laboratory was based on
colony morphology on chromogenic agar (CHROMagar, Paris,
France), microscopic morphology on corn-meal agar and rice
plus Tween agar (SSI Diagnostika, Hillerød, Denmark), growth
at 35C and 43C, and results obtained using the ATB ID32C
system (bioMe´rieux). In addition, rapid commercial tests for
the identiﬁcation of Candida dubliniensis and C. glabrata were
used increasingly during the study period (BICHRO-DUBLI
and Glabrata RTT; Fumouze Diagnostics, Simoco, Denmark).
Susceptibility testing
Susceptibility testing was performed according to EUCAST
discussion document E7.1 [17]. Manufacturers and stock
solutions were as follows: dimethylsulphoxide (DMSO)
(Sigma-Aldrich, Vallensbaek Strand, Denmark); ﬂuconazole
(Pﬁzer, Ballerup, Denmark; 10 000 mg ⁄L); amphotericin B
(Sigma-Aldrich; 5000 mg ⁄L in DMSO); caspofungin (Merck,
Sharp and Dohme, Glostrup, Denmark; 5000 mg ⁄L in DMSO);
itraconazole (Janssen-Cilag, Birkerød, Denmark; 5000 mg ⁄L
in DMSO); and voriconazole (Pﬁzer; 5000 mg ⁄L in DMSO).
Two-fold dilutions in RPMI medium with glucose 2% w ⁄v
were prepared in microtitre plates and stored at )20C until
use. Microtitre plates were read spectrophotometrically at
490 nm. The MIC was deﬁned as the lowest drug concentra-
tion giving 100% growth inhibition for amphotericin B or 50%
growth inhibition for the other compounds. Candida krusei
ATCC 6862 was included as a control strain in each run; the
MIC determinations were accepted if they were within the
published ranges for amphotericin B, ﬂuconazole, itraconazole
and voriconazole [18], and within 0.25–2 mg ⁄L for caspo-
fungin (for which no quality control range has yet been
published).
Consumption of antifungal compounds
Information concerning consumption of antifungal agents in
deﬁned daily doses (DDD) was available from the Danish
Medicines Agency and from hospital pharmacies serving the
participating university hospitals.
Statistical analysis
The infection rate was calculated by dividing annual numbers
of distinct episodes by either catchment population and
multiplying by 105, or by the numbers of non-psychiatric
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admissions and multiplying by 103. The strict deﬁnition of an
episode meant that the infection rate was close to the true
incidence, and therefore the two terms are used interchange-
ably. Fisher’s exact test was used for comparison of changes in
species distribution, and a chi-square test for trend was used
for comparing the proportion of C. glabrata isolates for which
the voriconazole MIC was >1 mg ⁄L. p values <0.05 were
considered to be statistically signiﬁcant.
RESULTS
Epidemiology
During the 3-year period from 2004 to 2006, 1089
episodes of fungaemia were registered for 1040
patients. The numbers of patients (324, 339, 377),
episodes (334, 363, 392) and isolates recovered (342,
382, 409) increased by 16.4%, 17.4% and 19.6%,
respectively, during the 3-year period. In contrast,
the size of the population in the catchment area
increased by 0.6%. Overall, the rate of fungaemia
was 0.51 ⁄ 1000 admissions, and 10.4 ⁄ 100 000 pop-
ulation, but a slight increase was observed when
comparing 2004 and 2006 (9.6 ⁄ 100 000 inhabitants,
95% CI 8.6–10.7 ⁄ 100 000 vs. 11.2 ⁄ 100 000 inhabit-
ants, 95% CI 10.1–12.3 ⁄ 100 000, respectively). The
proportion ofmales remained constant at 56%. The
median age rose slightly from 64.0 to 66.5 years
(range 0–94 years); only 1.9% of the patients were
aged <1 year (incidence 16.3 ⁄ 100 000), 4.4% were
aged <20 years (incidence 2.2 ⁄ 100 000), 50.0%
were aged >65 years (incidence 36.9 ⁄ 100 000),
and 36.5% were aged >70 years (incidence
38.3 ⁄ 100 000). The median age and the proportion
of isolates in each age group varied according to
species (Table 2). Notably, C. glabrata and C. krusei
were not recovered from any patient aged
<20 years.
The overall species distribution is shown in
Table 1. Candida spp. accounted for 98.1% of the
fungal isolates, with C. albicans being the pre-
dominant species (overall 59.8%). However, the
proportion of C. albicans varied considerably
among the participating hospitals, from 51.1% at
Hvidovre Hospital in Copenhagen to 67.6% at the
hospitals in the county of North Jutland. C. glab-
rata was the second most frequent species (overall
20.5%), again with considerable variation in
frequency according to hospital (11.2–33.8%)
and the blood culture system used. The variation
in distribution of C. glabrata between centres
using BACTEC (16.7%, 97 ⁄ 580) and those using
BacT ⁄ALERT (24.4%, 135 ⁄ 553) was statistically
signiﬁcant (p 0.0015). C. krusei was a rare isolate
(4.1%) throughout the entire study period.
During 2004–2006, the total number of C. albi-
cans isolates was stable, although the overall
proportion decreased signiﬁcantly, while the
number of C. glabrata, C. krusei and C. dubliniensis
isolates increased (Table S1, see Supplementary
material). None of these changes was caused by a
single-centre effect. Mixed infections involving
two fungal species occurred in 44 (4.0%) cases,
i.e., eight in 2004, 19 in 2005 and 17 in 2006 (2004
compared to 2005–2006, p 0.07). In 36 of these
cases, C. albicans was isolated in combination with
another yeast, with C. glabrata accounting for 29
cases. In total, 42 (95.5%) of the polyfungal
infections involved at least one isolate with
intrinsic decreased susceptibility to ﬂuconazole
(i.e., C. glabrata, Saccharomyces cerevisiae, C. krusei
and Rhodotorula spp.).
Antifungal susceptibility testing
Susceptibility testing for amphotericin B, caspo-
fungin, ﬂuconazole and itraconazole was per-
formed for 1025 (90.5%) isolates, and for
voriconazole for 951 (83.9%) isolates.
MIC distributions are shown in Table 3. All but
four isolates were susceptible to amphotericin B,
as deﬁned by an MIC of £1 mg ⁄L (one C. glabrata,
one C. krusei and two Fusarium spp. isolates had
an MIC of 2 mg ⁄L). For caspofungin, a uniform
bell-shaped population was revealed, with MICs
of £0.03–2 mg ⁄L; however, three isolates had an
MIC of 4 mg ⁄L (one each of Candida parapsilosis,
Candida guilliermondii and Rhodotorula spp.), and
12 (1.2%) isolates with an MIC ‡8 mg ⁄L were
detected (one Trichosporon asahii, four Cryptococcus
neoformans, four Fusarium spp. and three Candida
isolates (one C. albicans, one C. dubliniensis
and one C. parapsilosis). Within Candida spp., a
Table 2. Distribution of fungal isolates according to age
group
Species
No. (%) of isolates found in group aged (years)
<1 1–20 21–40 41–60 61–80 >80
Candida albicans 15 (71) 23 (77) 40 (62) 191 (61) 345 (58) 64 (58)
Candida dubliniensis 6 (9) 6 (2) 16 (3) 1 (1)
Candida glabrata 8 (12) 65 (21) 125 (21) 34 (31)
Candida krusei 2 (3) 18 (6) 26 (4) 1 (1)
Candida parapsilosis 4 (19) 4 (13) 4 (6) 11 (4) 21 (4) 1 (1)
Candida tropicalis 12 (4) 34 (6) 6 (5)
Candida spp. 2 (10) 2 (7) 1 (2) 5 (2) 15 (3) 2 (2)
Other fungi 1 (3) 4 (6) 3 (1) 12 (2) 1 (1)
Total 21 30 65 311 594 110
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tendency towards higher MICs of caspofungin
was observed for non-albicans isolates
(MIC50 0.5 mg ⁄L, range £0.06 to >8 mg ⁄L) com-
pared to C. albicans isolates (MIC50 0.25 mg ⁄L,
range £0.06 to >8 mg ⁄L) (Table 3).
The susceptibility patterns for the azoles were
more complex. Thus, most Candida isolates were
susceptible to ﬂuconazole and itraconazole, with
the exception of isolates belonging to the intrin-
sically less susceptible or resistant species C. glab-
rata and C. krusei. However, using the EUCAST
breakpoints for ﬂuconazole of S £2 mg ⁄L and
R >4 mg ⁄L [19], 13 Candida isolates, which were
not C. glabrata or C. krusei, were resistant (three
C. albicans with MICs of 8 to >16 mg ⁄L, one
Candida pelliculosa with an MIC of 8 mg ⁄L, and
one each of C. guilliermondii, Candida holmii, Can-
dida inconspicua, Candida kefyr, Candida lusitaniae,
C. parapsilosis, Candida tropicalis and Candida utilis,
all with MICs of ‡16 mg ⁄L). In addition, 12
Candida isolates had an MIC of 4 mg ⁄L (ﬁve
C. parapsilosis, three C. tropicalis, two C. guillier-
mondii, one C. albicans and one C. pelliculosa). In
total, 25 (2.2%) isolates of other Candida spp. had
an MIC of ‡4 mg ⁄L (Table 3). For itraconazole, 14
non-glabrata non-krusei Candida isolates had MICs
of >0.125 mg ⁄L (six C. tropicalis, three C. guillier-
mondii, two C. pelliculosa and one each of
C. albicans, Candida famata and C. holmii). Ten of
these 14 isolates were cross-resistant to ﬂucon-
azole. Finally, all C. albicans isolates had vorico-
nazole MICs of £0.125 mg ⁄L, while 19 C. glabrata
isolates had voriconazole MICs of >1 mg ⁄L. Such
isolates were detected with increasing frequency
during the 3-year period (2004, 1 ⁄ 40, 3%; 2005,
6 ⁄ 77, 8%; 2006, 12 ⁄ 86, 14%; p 0.03).
Nineteen of the 21 non-Candida isolates were
tested for antifungal susceptibilities. Nine were
S. cerevisiae (ﬂuconazole 4–16 mg ⁄L, itraconazole
0.25–2 mg ⁄L, voriconazole 0.125–0.5 mg ⁄L), four
were Cryptococcus neoformans (ﬂuconazole
4–16 mg ⁄L, itraconazole 0.06–0.5 mg ⁄L, vorico-
nazole 0.03–0.5 mg ⁄L), four were Fusarium spp.
(ﬂuconazole >16 mg ⁄L, itraconazole >4 mg ⁄L,
voriconazole 1–4 mg ⁄L), one was Rhodotorula sp.
(ﬂuconazole 1 mg ⁄L, itraconazole 4 mg ⁄L, voric-
onazole 4 mg ⁄L) and one was Trichosporon sp.
(ﬂuconazole 1 mg ⁄L, itraconazole <0.03 mg ⁄L,
voriconazole 0.06 mg ⁄L). Thus, overall, 29.8% of
the fungal isolates tested (305 of 1025) showed
decreased susceptibility to ﬂuconazole and ⁄ or
itraconazole (deﬁned as an MIC of ‡4 mg ⁄L and
‡0.25 mg ⁄L, respectively). There was an increase
in each year of the study, with 20.2% (65 ⁄ 321) in
2004, 28.2% (96 ⁄ 341) in 2005, and 35.3% (128 ⁄ 363)
in 2006 (p 0.02 comparing 2004 and 2005; p 0.0001
comparing 2004 and 2006).
Consumption of antifungal agents
The total consumption of antifungal agents in
Denmark is shown in Fig. 1. The total annual
usage of ﬂuconazole increased by 152% (from
13.6 to 34.4 DDD ⁄ 100 000 inhabitants ⁄day) dur-
ing the 5-year period from 2001 to 2006. For the
systemic azoles, 78% of usage was in the primary
healthcare sector (http://www.medstat.dk/
PackStatDataViewer.php).
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Fig. 1. Use of antifungal compounds (in daily deﬁned
doses, DDD) in Denmark between 2000 and 2006.
Table 3. MIC ranges and MIC50 and MIC90 values (mg ⁄L) for 1025 fungal isolates
Amphotericin B Caspofungin Fluconazole Itraconazole Voriconazolea
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Candida albicans £0.06–1 0.25 0.5 £0.06–1 0.25 0.5 £0.125–>16 0.25 0.5 £0.03–0.25 £0.03 0.06 £0.03–0.125 £0.03 £0.03
Candida dubliniensis £0.06–0.25 £0.06 0.125 £0.06–1 0.5 1 £0.125–1 0.25 1 £0.03–0.06 £0.03 0.03 £0.03 £0.03 £0.03
Candida glabrata £0.06–2 0.25 0.5 0 £ 0.06–2 0.5 1 0.5–>16 8 >16 £0.03–>4 1 2 £0.03–>4 0.25 1
Candida krusei 0.25–2 1 1 0.25–2 0.5 2 1–>16 >16 >16 £0.03–0.5 0.25 0.5 0.06–1 0.25 1
Candida parapsilosis £0.06–1 0.5 1 0.25–>8 2 2 0.125–>16 1 4 £0.03–0.125 0.06 0.125 £0.03–0.25 £0.03 0.06
Candida tropicalis 0.125–1 0.5 1 £0.06–2 0.5 1 0.125–>16 1 2 £0.03–1 0.03 0.25 £0.03–2 £0.03 0.25
Candida spp. £0.06–1 0.25 1 0.125–4 1 2 £0.125–>16 1 >16 £0.03–>4 0.125 1 £0.03–2 £0.03 0.25
Other fungi £0.06–2 0.5 2 0.5– >8 4 >8 1–>16 8 >16 £0.03–>4 0.5 >4 £0.03–4 0.5 4
aVoriconazole MICs were determined for 951 isolates.
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DISCUSSION
The ﬁrst comprehensive Danish study on funga-
emia, performed in 2003, revealed a notably high
annual incidence of fungaemia, which was con-
sistent with a steady increase in the numbers of
cases of candidaemia since the early 1990s [1].
The surveillance programme has subsequently
been extended to include two-thirds of the
Danish population, with data from the last
3 years showing a further increase, despite the
fact that all tertiary hospitals in Denmark were
already included in the ﬁrst study period.
Surveys in other Nordic countries report
annual rates of candidaemia in the range of
2–4.9 episodes ⁄ 100 000 inhabitants [2–4,8]. In this
context, the present estimated annual rate of
10.4 ⁄ 100 000 inhabitants seems very high, and is
also high when compared with candidaemia rates
in the rest of Europe, Canada, Iowa, Atlanta and
San Francisco, USA, which were in the order of
3–8 ⁄ 100 000 population, but is comparable to the
combined rate of 10 ⁄ 100 000 reported in a recent
survey in Connecticut and Baltimore, USA
[7,9,11,12,14,20].
The reason for the high rate of fungaemia in
Denmark is not clear. One hypothesis is that the
use of centrally drawn blood cultures from
patients in intensive care units may contribute to
a high incidence of fungaemia. However, the
proportion of blood cultures positive for coagu-
lase-negative staphylococci, which are microor-
ganisms that are frequently associated with
catheter infection, was 25–30% (data not shown),
i.e., comparable to proportions reported else-
where, which suggests that this is not the sole
explanation [21,22]. Applying the estimate of
Wenzel and Edmond [21] that 5% (2.5–10%) of
all patients admitted to hospitals will be affected
by a nosocomial infection, 10% of which will be
bloodstream infections, with 8% of these being
caused by Candida spp., a total of 294 (147–587)
candidaemia cases would be expected to be
detected annually in the present survey, which
is in close agreement with the number actually
observed. However, as the number of hospital
admissions in Norway is similar to that in
Denmark, a similar ﬁgure for candidaemia
should also be expected in Norway [23]; the
discrepancy illustrates that a number of issues
concerning fungaemia rates are not yet fully
understood.
The highest incidences of candidaemia were
observed among elderly patients, reaching an
incidence of 36.9 episodes ⁄ 100 000 among the
population aged >65 years. With the exception
of the Baltimore and Connecticut study, this is the
highest incidence reported in any population-
based survey [2,4,7,8,10,12,20]. A high incidence
was also revealed in infants (16.3 ⁄ 100 000), con-
ﬁrming the susceptibility to candidaemia of this
patient group [2,4,8]. The proportion of candidae-
mic patients aged >70 years was lowest for
C. parapsilosis (26.7%), but C. parapsilosis caused
only four of 21 cases of candidaemia in patients
aged <1 year. Hence, the higher proportion of
C. parapsilosis in younger age groups was con-
ﬁrmed, but without the marked over-representa-
tion among neonates reported in other studies
[3,10,24–27]. The proportion of candidaemic
patients aged >70 years was highest for C. tropi-
calis (50%), and was signiﬁcantly higher than for
C. parapsilosis. C. tropicalis is more frequent in
patients with underlying haematological disease,
and the increasing frequency of such disease in
the elderly population may account for the over-
representation of C. tropicalis in this age group.
The percentage of patients aged >70 years was
also higher for C. glabrata than for C. albicans
(39.6%), which is in accord with previous studies
[2,3,9,25,26,28].
Three species accounted for the continuous
increase in candidaemia over the 3-year period,
namely C. glabrata, C. krusei and C. dubliniensis.
While the increase of C. dubliniensismay reﬂect, at
least in part, enhanced efforts to distinguish
C. dubliniensis from C. albicans during the study
period, the increase of C. glabrata and C. krusei
cannot be explained by changes in methodology.
The total usage of ﬂuconazole has increased
considerably in Denmark during recent years,
i.e., by 153% between 2001 and 2006, and it is
possible that this increased consumption may
have contributed to the increase in the number of
isolates and percentages of these species (which
have intrinsically higher MICs).
Recent reports have suggested that the choice
of blood culture system may inﬂuence the recov-
ery of C. glabrata, and that the BACTEC system
may be inferior to the BacT ⁄ALERT system in this
respect [2,29]. The present data support this
observation, as the recovery rate of C. glabrata
was signiﬁcantly lower at centres using the
BACTEC system than at centres using the
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BacT ⁄ALERT system. It is therefore suggested
that the mycosis medium is included at centres
using the BACTEC system when a patient is at
risk for candidaemia.
A low prevalence of resistance to amphoteri-
cin B and caspofungin was revealed, but unlike
the ﬁrst year of surveillance, in which no Candida
isolates showed elevated caspofungin MICs,
three Candida isolates were found to have caspo-
fungin MICs >8 mg ⁄L. The low level of resis-
tance is not surprising, as amphotericin B is a
broad-spectrum compound that has been used
for many years without any noticeable selection
of resistance. Usage of amphotericin B and
(recently introduced) caspofungin is also much
less than that of azoles. Reduced susceptibility to
azoles was mainly demonstrated in isolates with
intrinsic resistance mechanisms to azoles, i.e.,
C. glabrata, C. krusei and some non-Candida iso-
lates. However, interestingly, the percentage of
isolates that were not fully susceptible to ﬂuco-
nazole and ⁄ or itraconazole accounted for 35% of
the total cases of fungaemia in 2006. Treatment
regimens should take this high percentage of
ﬂuconazole-non-susceptible isolates into account.
In this setting, the use of ﬂuconazole would be
safe if restricted to cases in which: (i) suscepti-
bility testing has already been undertaken; (ii)
susceptibility is reliably indicated by the species
identiﬁcation; or (iii) close surveillance of the
individual patient suggests that ﬂuconazole-
resistant yeasts are a rare cause of fungaemia.
This is in line with the recent recommendations
by Laupland et al. [20], which were based on
similar proportions of isolates with reduced
susceptibility to ﬂuconazole. This emphasises
the need for rapid species identiﬁcation and
susceptibility testing, which is now facilitated by
commercially available rapid identiﬁcation tests
for C. glabrata and C. krusei.
In conclusion, the present study revealed a
remarkably high and continuously increasing
incidence of fungaemia in Denmark compared
to other Nordic countries and worldwide. The
proportion of isolates with decreased susceptibil-
ity to ﬂuconazole and ⁄ or itraconazole exceeded
one-third. These worrying ﬁndings underline the
importance of monitoring the situation and
adjusting the initial choice of antifungal agents
and the use of antifungal prophylaxis according
to the local patterns of epidemiology and anti-
fungal susceptibility.
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